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Abstract
Genotyping chips for rare and low-frequent variants have recently gained popularity with the
introduction of exome chips, but the utility of these chips remains unclear. These chips were
designed using exome sequencing data frommainly American-European individuals,
enriched for a narrow set of common diseases. In addition, it is well-known that the statistical
power of detecting associations with rare and low-frequent variants is much lower compared
to studies exclusively involving common variants. We developed a simulation program
adaptable to any exome chip design to empirically evaluate the power of the exome chips.
We implemented the main properties of the Illumina HumanExome BeadChip array. The
simulated data sets were used to assess the power of exome chip based studies for varying
effect sizes and causal variant scenarios. We applied two widely-used statistical approaches
for rare and low-frequency variants, which collapse the variants into genetic regions or
genes. Under optimal conditions, we found that a sample size between 20,000 to 30,000
individuals were needed in order to detect modest effect sizes (0.5% < PAR > 1%) with 80%
power. For small effect sizes (PAR <0.5%), 60,000–100,000 individuals were needed in the
presence of non-causal variants. In conclusion, we found that at least tens of thousands of
individuals are necessary to detect modest effects under optimal conditions. In addition,
when using rare variant chips on cohorts or diseases they were not originally designed for,
the identification of associated variants or genes will be even more challenging.
Introduction
Since the introduction of GenomeWide Association Studies (GWAS), a large number of com-
mon single nucleotide variants (SNVs) have successfully been associated to many complex dis-
eases [1]. However, both the proportion of the phenotypic variability explained by these
variants and the effect sizes are rather small for most studied traits. This issue has been widely
discussed and is referred to as “missing heritability” [2–5]. This term suggests that genetic
causes that are difficult to detect with a classic SNV array design are involved in the phenotype
of interest. Such causes may be gene-gene and gene-environment interactions, chromosomal
PLOSONE | DOI:10.1371/journal.pone.0139642 October 5, 2015 1 / 13
OPEN ACCESS
Citation: Page CM, Baranzini SE, Mevik B-H, Bos
SD, Harbo HF, Andreassen BK (2015) Assessing the
Power of Exome Chips. PLoS ONE 10(10):
e0139642. doi:10.1371/journal.pone.0139642
Editor: Joseph Devaney, Children's National Medical
Center, Washington, UNITED STATES
Received: June 8, 2015
Accepted: September 14, 2015
Published: October 5, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The study was funded by the University of
Oslo (www.uio.no), grant number 531217/1231
(CMP); and Norwegian Research Council (NOTUR),
grant number NN9311K/1734 (CMP, BKA, BHM). The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
aberrations, epigenetic differences, or less frequent causal variants with minor allelic frequen-
cies of 0.5% to 5% (low-frequency variants) or less than 0.5% (rare variants). Several of such
rare and low frequent SNVs have been shown to associate with complex diseases with odds
ratios (ORs) around 3 (e.g. [6–8]). Some structural variants associated to psychiatric disorders
have been reported with even higher ORs (e.g. [9–12]). For example, a structural variant has
been shown to give as much as a 20 fold increased risk for autism spectrum disorder [10].
The importance of considering allelic variants in coding regions, as well as budgetary and
practical restrictions for whole exome sequencing in large studies, motivated the construction
of the “exome chips” [13, 14]. A number of studies that used exome chips have already been
published [15–29], with several of the studies reporting negative findings. However, pheno-
type-associations of some variants and genes have been discovered using this chip. Igartua et.
al. [20] found one low-frequent variant associated to asthma when using a single variant test in
a multi-ethnic cohort of 11,225 individuals. By using a collapsing approach (Sequence Kernel
Association Test [30]), two additional genes were identified. Within a cohort of 8,229 Finnish
individuals, Huyghe et.al. [16] identified new associations of low-frequent loci to fasting glu-
cose levels. In a follow up case-control study by Wessel et.al., including more than 158,000
individuals, and by using statistical approaches designed for low-frequency or rare variants,
one novel genetic association was discovered, driven by four rare non-synonymous SNVs
within this gene [21]. With a multi-ethnic cohort of 56,000 individuals typed on the exome
chip, four low-frequent variants were identified to be associated with coronary heart disease,
using a single variant test. Furthermore, Tachmazidou et.al. identified a significant cardio-pro-
tective variant which was common in an isolated population, however this variant is assumed
to be rare in outbred European populations [28].
The design of the exome chip was based on pooled exome sequencing data of 16 contrib-
uting studies [31], which comprised 12,031 individuals. These studies were highly enriched
for European Americans, which accounted for approximately three-quarters of the
sequenced individuals [20]. This has caused a concern concerning the generalizability of
using low-frequency and rare variants in studies across populations. These variants are more
likely to be evolutionary young [32], and thus, population specific. Approximately 65% of
the contributing individuals were enriched for lifestyle disorders (Cardiovascular diseases,
Type 2 Diabetes, Overweight, Lipid extremes, Body Mass Index extremes). Additionally,
20% of the samples were collected from psychiatric disorder cohorts (autism spectrum,
schizophrenia and depression). The remaining 15% were samples from the thousand
genomes project, a Sardinian cohort (SardiNIA sequencing project), and two cancer studies
(S1 Table). In the design of this chip many common disease groups were absent, including
autoimmune and neurodegenerative diseases. The exome chip consortia focused on captur-
ing low-frequency and rare, non-synonymous variants, which were observed more than
three times in at least two different cohorts. Most of the variants assayed on the exome chips
were rare (84%), 9.2% were low-frequent, and 5.8% were common. Both the companies Illu-
mina and Affymetrix produced a genotyping chip for low-frequent and rare, exonic variants
based on the proposed list of SNVs from the Exome Chip Consortia, leading to the Illumina
HumanExome BeadChip Array and the Axiom Exome Genotyping Array, respectively.
Since the power to detect an association between a single SNV and a phenotypic trait
decreases with decreasing minor allelic frequency, there has been a need for new statistical tools
for analysing low-frequent and rare variants. These variants often occur at different locations
throughout the considered genes. Therefore, methods for this type of variants have been devel-
oped, which aim to collapse variants along a meaningful biological unit (i.e. gene, promoter,
enhancer, etc.) into one test statistic. This includes methods which contrast the mean number of
observed variants between cases and controls, such as Weighted Sum Statistic (WSS) [33] and
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Replication Based Test (RBT) [34], or adaptive burden tests, like the Kernel Based Adaptive
Clustering Method [35]. Another general class of methods comprises variance contrasting
methods, which compare the variation of alleles between cases and controls, such as the C(α)–
method [36] and Sequence Kernel Association Test (SKAT) [30]. While several different meth-
ods have been compared extensively (e.g.[37–42]), no single gold standard has been established.
On the contrary, it is also recommended to use different kinds of methods [37, 41].
With respect to the increasing use of exome genotyping chips, we aimed to investigate the
sample size requirements for association studies using these chips. The power for different sta-
tistical approaches for analysing low-frequent and rare variants has been investigated and com-
pared to each other by others [30, 33, 37, 40, 41]. The corresponding simulations were
performed for varying properties of a single unit (i.e. gene), thereby focusing on the compari-
son of statistical methods with respect to the detection of rare and low-frequency variants.
These simulations did not take the whole variety of possible allelic frequencies into account,
neither the dependencies between the variants corresponding to a real chip design. Thus, these
power simulations are only representative for certain allelic frequencies, ignoring the underly-
ing realistic allele frequency distribution and dependency patterns.
We developed a simulation pipeline, which relies on simulations based on all variants of the
underlying chip design, thereby capturing the entire allele frequency spectrum and underlying
dependencies between the variants. In this paper, we mimicked the structure of the Illumina
HumanExome BeadChip array, but the available pipeline can also be applied to any other
(future) chip designs.
Material and Methods
Simulation of genotypes
As a starting point for the simulations in this paper, we simulated a data pool of genotypes for
200,000 unrelated individuals using the approach described in Basu et.al.[41], with some modi-
fications. To mimic the chip as accurately as possible, we used the publicly available allele fre-
quencies reported by the Exome Chip Consortia. From their documentation [31], we
reproduced the allele frequency of 212,353 non-synonymous SNVs, thus including 96% of the
coding variants on the chip. In order to mimic the dependency structure between the variants,
we applied a correlation function based on the position of the variants on the exome chip [43].
Simulation of phenotypes
To construct case-control phenotypes, we used the same approach as Madsen et.al. [33, 37] fix-
ating the population attributable risk (PAR) for all variants, and calculating a genotype relative
risk (GRR) based on the given PAR and the minor allele frequency (MAF) (see S1 Algorithm
Eq 1). We assumed that all causal rare variants were deleterious, and that no variants had any
protective effect. The probability of an individual being diseased based on their genotype, was
calculated as the product of their GRRs, multiplied by a fixed incidence (see S1 Algorithm Eq
2). This was done for each individual separately. The relation between GRR and PAR is such
that for a given MAF, and PAR, a linear increase in PAR corresponds to a linear increase in
GRR. If the PAR was fixed, then an increase in the MAF corresponded to an inverse propor-
tional decrease in GRR.
We considered two different scenarios for the structure of the simulated causal genes. In the
first scenario, 100% of the SNVs in each analysed gene were causally linked to the phenotype.
In the second scenario, the same genes were analysed, but only 50% of the SNVs within each
gene where causally linked to the phenotype, thus decreasing the signal to noise ratio.
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Statistical Methods
To assess the sample size required to obtain sufficient power, we applied two widely used statis-
tical methods for rare variants: SKAT [30] andWSS [33]. In SKAT which is a generalization of
the variance contrast test (C(α) method [36]), we used an adaptive weighting for each variant
(the Beta(MAF, 0.5, 0.5) kernel). The WSS test is an adaptive sum test, for each unit, it calcu-
lates a weighted sum for all individuals, and then permutes the ranking of those sums, if the
cases are consistently ranked on top, this will correspond to a low p-value. The weight for each
variant is determined by the MAF and the case-control ratio. The two statistical methods used
here were chosen as representatives for two common classes of methods for rare variant analy-
sis; variance contrasting tests and sum tests. In both methods, all the genes are tested indepen-
dent of each other. The weights applied to all variants have similar structure for both SKAT
andWSS. In both methods, the weighing is such that common alleles will receive a low weight,
while empirically rare variants will have a high weight.
Power Simulations. We investigated the power performance by drawing sample sizes of
10,000 (10k), 20k, 30k, 60k, and 100k individuals from the genotype pool described above. The
simulated case-control ratio was 1:1. To assess the power under the different scenarios, we ran-
domly selected a set of 100 genes. The distribution of allelic frequencies of this subset was simi-
lar to the corresponding allelic frequency distribution of all SNVs on the chip (S1A Fig). The
mean number of SNVs per drawn gene was 18. 50 simulated datasets including 100 genes were
generated for each combination of effect size, scenario and number of individuals. For each
simulated dataset, the genes were tested on the Bonferroni adjusted genome-wide threshold
based on the number of reproduced genes on the chip (19,975), thus neglecting findings in the
genes without any simulated effect. The power was defined as the percentage of true discovered
genes within one replicate. The overall power was presented as the mean power over all replica-
tions along with the empirical 95%—confidence interval.
Null simulations. We provide two types of simulations without adding an effect on the
simulated genotypes (0% PAR on all causal variants). First, we aim to characterize the imple-
mented statistical methods with respect to their ability to detect false positive findings. To
achieve that, we used the 50 simulated datasets for 60k samples including 100 genes described
above and assigned case-control status randomly. For each simulated dataset, we evaluate the
percentage of false positives and present the mean percentage across all simulated datasets. In
this simulation, we choose a 5% threshold for the p-values of each gene. A genome-wide
threshold could have been simulated here as well, but would require a much larger number of
null genes and thus dramatically increase the computational burden. Second, we wanted to
show the genome-wide performance of the tests with no underlying effect present for the
underlying chip structure considered in this paper. Thus, we simulated 10 datasets including
all genes (19,975) for two different numbers of individuals (10k, 60k), assigning the case-con-
trol status arbitrarily.
The simulations and power assessment where done using the computer program R 3.2.1
[44], with the additional packages: Matrix [45], MultiPhen [46] and snpStats [47].
The simulation program can be received from the authors by request.
Results
Both of the statistical methods keep the Type-I error level, with SKAT being slightly more con-
servative than WSS. The corresponding estimated mean percentages of false positives were
0.0465 (SKAT) and 0.0503 (WSS) when applying the 5% Type-I error threshold (see Material
and Methods). In order to understand the performance of the exome chip when no effects are
present, the distribution of the p-values across all 19,975 genes was visualized in a QQ-plot
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(Fig 1A and 1B). It can be seen that SKAT is more conservative, with no false positive observa-
tions, while WSS had an average of 4.7 false positive for a 10k sample, and an average of 5.4
false positive in a 60k sample, in a genome wide scan.
To assess the power of the underlying chip under the non-null distribution, we simulated
an increasing effect size (PAR) for different sample sizes based on two statistical approaches
Fig 1. QQ-plot for power analysis and null simulation, the diagonal line represent the expected value and the horizontal line the Bonferroni cut-off.
(A) QQ-plot for one realization of the null simulation for 10k, SKAT is plotted in red/orange andWSS in dark green/light green. (B) QQ-plot for one realization
of the null simulation for 60k, SKAT is plotted in red/orange, andWSS in dark green/light green. (C) QQ-plot of—log p-values for SKAT andWSS, given 100%
causal SNVs within the causal genes, and a sample size of 10k. False negative is in lighter colors (SKAT; light green, WSS; orange) and true negative is
colored in gray. (D) QQ-plot of—log p-values for SKAT andWSS, given 100% causal SNVs within the causal genes, and a sample size of 60k. False
negative is in lighter colors (WSS; orange) and true negative is colored in gray.
doi:10.1371/journal.pone.0139642.g001
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(SKAT and WSS). We first investigated a scenario where all variants within a gene were
causal. In this scenario, both SKAT and WSS reached a power of 80% with a PAR less than
1.4% (SKAT) and 2.4% (WSS) per SNV, and SKAT converged to maximum power for 1.5%
for sample sizes above 10k (Fig 2A and 2B). SKAT and WSS had approximately the same
speed of convergence when all variants were assigned the same weight in SKAT (data not
shown). For sample sizes larger than 20k individuals, the rate of convergence of power
evolved more than twice as fast in SKAT as compared to WSS. The increase in power for
sample sizes above 60k individuals was marginal in SKAT. However, in WSS, the rate of con-
vergence between the different sample sizes was more pronounced, with notable differences
in convergence for sample sizes of 60k and 100k individuals. For small effect sizes
(PAR< 0.5%) and a sample size of 10k, WSS converged marginally faster than SKAT. To
evaluate the global performance of the chip for a given PAR in this scenario, we applied both
WSS and SKAT to all genes, with a sample size of 10k and 60k. The result for PAR = 0.3% on
all causal variants is presented in Fig 1C and 1D. Fig 1 shows that SKAT is more conservative
in its p-value estimation than WSS, both for the null simulation and with an effect size of
0.3% PAR for a sample size of 10k.
When only 50% of the SNVs within each unit were causal, a much slower convergence
was observed for both methods (Fig 2C and 2D). For 10k individuals, a PAR of 6.5% was
needed to obtain 80% power with SKAT, whereas WSS reached 70% power within 8.0% PAR
on each causal variant. To reach 80% power with WSS within 6% PAR, a sample size of at
least 30k was needed. For SKAT, a sample size of at least 30k did converge to 100% power
for PAR up to 7%. This is a substantial loss of power, compared to the assumption that all
SNVs within each gene were causal. In that case, half of the effect sizes were sufficient to
reach the same power. When considering sample sizes larger than 10k individuals, 80%
power is reached within a PAR of 1.4% for SKAT. WSS reached 80% power within 5.6% PAR
for sample size of 30k. For sample sizes above 10k, SKAT converged to maximum power at
2% PAR. In WSS, the convergence was substantially slower, with none of the sample sizes
converging to 100% within their tested range of PAR.
In order to assess how many individuals would be needed for a given power, we plotted
power as a function of sample size (Fig 3). Under the assumption of 100% causal variants per
unit, the best performance was reached with a sample size of 60k individuals or more, where
both SKAT and WSS were above the 80% threshold in for the two biggest effect sizes pre-
sented (PAR = 0.5% and 1%). For WSS, a larger sample size was consistently needed to obtain
the same power as SKAT in the same scenarios (Fig 3A and 3B). When 100% of the SNVs
were causal, the power of WSS was comparable to the power of SKAT when only 50% of the
variants were causal (Fig 3B and 3C). For effect sizes of 0.2% PAR in the 50% scenario, a sam-
ple size of 60k was sufficient to reach 80% with SKAT, but for WSS, 100k was needed (Fig 3C
and 3D).
In order to investigate the relationship and distribution of the effect sizes GRR and PAR of
the causal variants, we plotted a histogram of the GRR for different PAR (S1B Fig). For a fixed
PAR of 0.5% on all causal variants, the GRR range in our simulated data was between 1 and 70,
with a median of approximately 12. Since the GRR scales linearly for small PAR, a doubling of
PAR to 1%, resulted in a doubling of the GRR. The corresponding GRR then had a maximum
of 140 and a median of 24, as seen in S1B Fig.
Discussion
In this work we addressed the utility of genotyping chips for rare variants under optimal condi-
tions, illustrated by simulating the content of the Illumina HumanExome BeadChip array
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under different scenarios. Given a homogenous population (as was used for the design of the
chip), we found that to detect a true association with 80% power, for a PAR around 1.5% on
each causal variant in the presence of noise, a sample size of at least 20k individuals were
needed under optimal conditions. Thus, the chip performance was acceptable for large
(PAR> 1%) effects even in relatively small cohorts (10-20k). For small effect sizes
Fig 2. Power plots for increasing PAR for SKAT andWSS for multiple testing adjusted analyses, for different sample sizes. The dashed line
represent the median power, with the covered area is the inter quantile range of 25% to 75% power. (A) 100% causal SNVs within all genes, estimated with
SKAT. (B) 100% causal SNVs within each gene, estimated with WSS. (C) 50% causal SNVs within each gene, estimated with SKAT. (D) 50% causal SNVs
within each gene, estimated with WSS.
doi:10.1371/journal.pone.0139642.g002
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(PAR< 0.5%) in the presence of noise, a balanced case-control study with a total sample size
of 30k to 50k individuals would be required.
Our assumption of sample homogeneity of conferred risk for the SNVs in this analysis is
not likely to be met in most association studies. This is mainly due to population specific rare
variants. We also assumed that all rare coding causal variants were deleterious. Although some
variants may be protective, the majority of rare coding alterations are believed to be either
harmful or have low phenotypic effect [14], thus making our assumption a reasonable choice.
We have focused our simulations on two different scenarios, one where 100% of the assayed
Fig 3. Power for increasing sample sizes and different PAR values after multiple testing adjusted analyses. (A) 100% causal SNVs within all genes,
estimated with SKAT. (B) 100% causal SNVs within each gene, estimated with WSS. (C) 50% causal SNVs within each gene, estimated with SKAT. (D) 50%
causal SNVs within each gene, estimated with WSS.
doi:10.1371/journal.pone.0139642.g003
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alleles within the gene were deleterious, and the other where 50% of the alleles were deleterious.
A scenario where all detected variants within a gene are causal to disease is very unlikely, but
represents an upper bound on the power estimate for collapsing methods. In earlier studies
which identified associated genes, the fraction of causal rare and low-frequent SNVs within the
gene was estimated to be as low as 5% [29]. For the gene discovered to be associated with
psychophysiological endophenotypes by Vrieze et.al. the association seemed to be driven by
two alleles, which represent 10% of the variants in this specific gene on the exome chip [27].
One of these variants was low-frequent (MAF = 1.25%) and the other one rare (MAF = 0.3%)
[27]. 40% of the rare coding exome chip variants within a gene associated to higher fasting glu-
cose levels showed a strong individual association to this phenotype [21].
An important issue is the enrichment of SNVs associated with certain diseases in the design
of the exome chip. Many common complex disease groups were not represented in the cohorts
used to design the chip, leaving the possibility that rare variants which may be strong risk fac-
tors for these diseases were not included on the chip. The rest of the SNVs included may be
neutral or have very small phenotypic effects. This will most likely result in sub-optimal perfor-
mance in studies of diseases that were not considered when designing the exome chips.
Although the difference in mean power between SKAT andWSS analyses was not substantial,
SKAT consistently outperformedWSS, which is in line with previous studies [37]. Furthermore,
SKAT also outperformedWSS on elapsed computational time, where the R implementation of
SKAT could benefit from parallelization on a cluster computer infrastructure.
The simulation pipeline developed here could be adapted to different chip designs. This pro-
gram is only dependent on allele frequencies and positions, since the linkage disequilibrium
(LD) between variants was modelled with a distance function. Furthermore, the algorithm is
flexible in its implementation, so it can be applied to assess the performance of any other chip
design, under different scenarios. In some simulation studies for assessment of rare variant
methods, a genome wide p-value cut-off was not used [37, 41] and the allele frequency range
was much wider. Simulations were performed on a single unit (i.e. genes) which included sev-
eral variants, leaving out valuable information about realistic underlying allele frequencies and
dependency patterns. In our study, we mimicked the properties of the exome chip, increasing
both usability and reliability of our results.
There is no standard algorithm for simulating effects on genetic variants, this has led to a sit-
uation where the reported results can vary depending on the implemented methods and
assumptions. Two popular approaches for emulating effect sizes are Odds Ratio (OR) modelling
and Risk Ratio (RR) modelling. Although these approaches are quite different, when the num-
ber of observed genotypes is small, both the OR and the RR will be approximately the same.
When the GRR was empirically estimated from the simulated data set, they were consis-
tently lower than expected from the equation used to generate them (S1 Algorithm Eq 1). This
indicates that the GRR presented in S1B Fig was overestimated, since it is theoretically calcu-
lated, and not empirically assessed.
The collapsing methods tests each gene (unit) and the power presented in Figs 2 and 3 on
the y-axis are gene-wise. However, the effect applied on the genotypes (x-axis in Fig 2), was per
SNV and not per gene. When considering genes, it is important to note that the disruption of
any coding element may be contributing to disease risk, and different variants within a gene
can all disrupt the gene product, with observed mild effect sizes for each variant. For this rea-
son, many different variants within the same gene may be underlying the same trait or disease.
By using the collapsing statistic on a gene instead of testing individual variants, the sample
sizes requirement may therefore be smaller. By selecting genes at random in the data simula-
tion process, we study the variety of genes on the chip, without using the entire data set, thereby
decreasing the computational load. Since the underlying allelic frequencies were properly
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presented, this gives a good indication of the overall performance of the chip, however, the
actual performance for each particular gene may vary from gene to gene.
While recent studies using exome chips have identified associations between low-frequent
or rare variants and disease, the identified variants have not yet contributed substantially to
explaining “The missing heritability”. Few of the studies have reported variants with minor
allele frequency below 0.5% to be associated with disease [21, 24, 26–28]. Our study indicates
that some negative reports may suffer from insufficient sample sizes and the special design of
the exome chips as explained above.
In our study we have only considered “perfectly called” variants, i.e. we have not introduced
any errors in the genotype calling algorithms. This may be an important issue for rare and low-
frequency genotyping chips, where calling the variants has proved to be challenging [48].
In conclusion, we found that a very large sample size, in the order of tens of thousands is
needed to detect modest effects under optimal conditions. For effect sizes less than 0.2% PAR,
around 100,000 individuals should be studied to have enough power to reach genome wide sig-
nificant results.
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